SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+25.2%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$697M
AUM Growth
+$697M
(-5.3%)
Cap. Flow
-$125M
Cap. Flow
% of AUM
-17.88%
Top 10 Holdings %
Top 10 Hldgs %
45.64%
Holding
97
New
21
Increased
21
Reduced
26
Closed
24
Top Buys
| 1 |
Vericel Corp
VCEL
|
$14.1M |
| 2 |
Celcuity
CELC
|
$10.7M |
| 3 |
HCA Healthcare
HCA
|
$8.29M |
| 4 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$7.81M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$7.65M |
Top Sells
| 1 |
United Therapeutics
UTHR
|
$29.6M |
| 2 |
Illumina
ILMN
|
$25.7M |
| 3 |
CVS Health
CVS
|
$17.8M |
| 4 |
Envista
NVST
|
$15.7M |
| 5 |
Eli Lilly
LLY
|
$15.3M |
Sector Composition
| 1 | Healthcare | 97.09% |
| 2 | Consumer Staples | 1.8% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
EDAP
1
EDAP TMS
EDAP
$84.5M
| $54.7M | 7.85% | 5,134,430 +244,685 | +5% | +$2.61M |
|
|
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $45.3M | 6.5% | 2,114,728 -387,873 | -15% | -$8.3M |
|
|
3
United Therapeutics
UTHR
$13.8B
| $35.7M | 5.12% | 128,268 -106,591 | -45% | -$29.6M |
|
4
BioAtla
BCAB
$26.7M
| $34.8M | 5% | 4,220,397 +819,894 | +24% | +$6.76M |
|
5
Arcellx
ACLX
$3.85B
| $34.2M | 4.9% | 1,102,447 -137,466 | -11% | -$4.26M |
|
6
Surmodics
SRDX
$487M
| $26.5M | 3.8% | 775,311 +6,833 | +0.9% | +$233K |
|
|
7
Vericel Corp
VCEL
$1.83B
| $23.9M | 3.43% | 908,997 +534,997 | +143% | +$14.1M |
|
8
Charles River Laboratories
CRL
$8.04B
| $22.2M | 3.18% | 101,850 -27,250 | -21% | -$5.94M |
|
9
iRadimed
IRMD
$921M
| $21.1M | 3.02% | 745,004 +60,314 | +9% | +$1.71M |
|
10
Organogenesis Holdings
ORGO
$653M
| $19.8M | 2.84% | 7,363,063 +874,000 | +13% | +$2.35M |
|
11
CVRx
CVRX
$205M
| $18.6M | 2.67% | 1,014,640 -44,400 | -4% | -$815K |
|
12
Vaxcyte
PCVX
$4B
| $18.6M | 2.67% | 387,950 +52,300 | +16% | +$2.51M |
|
|
13
Celcuity
CELC
$2.17B
| $17M | 2.43% | 1,210,228 +766,316 | +173% | +$10.7M |
|
14
Krystal Biotech
KRYS
$4.27B
| $14.9M | 2.14% | 188,217 -19,115 | -9% | -$1.51M |
|
15
C4 Therapeutics
CCCC
$185M
| $14.4M | 2.07% | 2,440,843 +999,330 | +69% | +$5.9M |
|
|
16
Eli Lilly
LLY
$657B
| $14.3M | 2.05% | 39,100 -41,700 | -52% | -$15.3M |
|
|
NARI
17
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $14.3M | 2.05% | 224,550 +122,942 | +121% | +$7.81M |
|
18
Exact Sciences
EXAS
$8.98B
| $14.2M | 2.04% | 287,300 +142,500 | +98% | +$7.06M |
|
19
Tandem Diabetes Care
TNDM
$845M
| $14M | 2.02% | 312,500 -102,700 | -25% | -$4.62M |
|
20
Humana
HUM
$36.5B
| $13.7M | 1.97% | 26,750 +12,550 | +88% | +$6.43M |
|
21
The Beauty Health Co
SKIN
$264M
| $12.5M | 1.8% | 1,376,368 -1,289,508 | -48% | -$11.7M |
|
|
INBX
22
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $11.8M | 1.69% | 478,302 +114,400 | +31% | +$2.82M |
|
23
Inspire Medical Systems
INSP
$2.77B
| $11.6M | 1.67% | 46,200 -21,200 | -31% | -$5.34M |
|
24
Keros Therapeutics
KROS
$618M
| $11.2M | 1.61% | 233,116 +87,116 | +60% | +$4.18M |
|
25
ESSA Pharma
EPIX
$11.4M
| $9.75M | 1.4% | 3,869,392 +1,228,853 | +47% | +$3.1M |
|